• Public Affairs

  • ACOEM Comments to FDA on Opioid Prescribing Activity

    March 15, 2018

    Dockets Management Staff (HFA-305)
    U.S. Food and Drug Administration
    5630 Fishers Lane, Room 1061 
    Rockville, MD 20852 

    Re: FDA–2017–N–6502

    To Whom It May Concern:

    On behalf of the American College of Occupational and Environmental Medicine (ACOEM), I am providing comments
    in response to the January 30 hearing held by the U.S. Food and Drug Administration — “Opioid Policy Steering
    Committee: Prescribing Intervention — Exploring a Strategy for Implementation.”   

    The current national dialogue about the use of opioids in medical treatment provides an example of the tension between
    process and outcomes — with the discussion increasingly focused on the importance of functional outcomes as the best
    assessment measure for opioid effectiveness. The recent creation of new strongly outcome-oriented guidelines and
    standards for opioid treatment offered by multiple organizations, is a signal of the importance of creating consistent,
    agreed-upon, outcome measures to achieve value. If more providers prescribing opioids were focused on similar functional
    outcomes as their treatment goal, the health system as a whole would be better equipped to reduce opioid abuse.1

    Functional outcomes refer to the patient’s ability to perform everyday activities such as exercise, driving, walking,
    household duties, and work. It is well known that opioids are not the only, nor best, treatment for non-acute pain.
    In addition, their use should not be extended beyond the generally short period needed to assuage acute pain. However,
    physician who are not monitoring the patient’s functional progress and are recording only pain scale responses are likely
    to over-prescribe opioids. The major reason providers are not following these goals is that they are not included in the
    routine medical record nor is functional status a required element in the electronic health record (EHR).

    We are requesting that the FDA petition the Office of the National Coordinator for Health Information Technology (ONC)
    to investigate the feasibility of requiring an element reflecting patient function be added to the EHR. Assessment of patient
    function is the mainstay in determining when opioids may be needed, how long they should be continued and how to prescribe
    them in a chronic pain setting.

    We note that numerous tools are available for assessing functional improvement. The AMA and the CDC opioid guidelines suggest
    that clinicians use validated instruments such as the three-item “Pain average, interference with Enjoyment of life, and
    interference with General activity” (PEG) Assessment Scale to track patient outcomes.2,3,4 However there are also other
    validated functional scales available.   

    While not specifically related to opioids, the consistent use of care focused on functional outcomes has been shown to
    decrease the cost of medical care and the resulting disability from an injury in working populations. Thus, benefits from
    the addition of this element to the EHR are likely extend significantly beyond the isolated population of those eligible for
    opioid use.

    Opioid prescribing activity is unlikely to conform to guideline recommendations and thus decrease inappropriate prescribing
    unless functional elements are available in the EHR. Therefore, ACOEM requests that the FDA encourage ONC to include this
    element in the EHR in order to address the opioid crisis.

    Thank you for your consideration of these comments.


    Charles M. Yarborough III, MD, MPH, FACOEM 



    2CDC Guideline for Prescribing Opioids for Chronic Pain — United States, 2016

    3Krebs EE, Lorenz KA, Bair MJ, et al. Development and initial validation of the PEG, a three-item scale assessing pain
    intensity and interference. J Gen Intern Med. 2009;24:733–8.

    5Recommendation 1. Nonpharmacologic therapy and nonopioid pharmacologic therapy are preferred for chronic
    pain. Clinicians should consider opioid therapy only if expected benefits for both pain and function are anticipated to
    outweigh risks to the patient. If opioids are used, they should be combined with nonpharmacologic therapy and nonopioid
    pharmacologic therapy, as appropriate (recommendation category: A, evidence type: 3). CDC Guideline for Prescribing
    Opioids for Chronic Pain — United States, 2016.

    6https://www.mdguidelines.com -- ACOEM Guidelines Opioids April 2017 -- including tracking functional activities
    and discontinuing opioids when no functional gain is achieved.